özkan alan

Md, Doç. Dr, medikal onkoloji, tıbbi onkoloji uzmanı Cerrahpaşa Tıp Fakültesi

[özkan alan @alan_ozkan]

Kanser artık çaresiz değil.
Akıllı ilaçlar ve yeni tedavi seçenekleriyle onkolojide oyunun kuralları değişiyor.
Pankreas ve akciğer kanseri başta olmak üzere, kanser tedavisindeki güncel gelişmeleri TRT Haber’de konuştuk.

[TRT HABER @trthaber]

Kanser tedavisinde umut veren gelişmeler yaşanıyor. Pankreas kanserinde yaşam süresini iki katına çıkarabilen ilaç gündeme geldi.

Uzmanlar, akıllı ilaçların kullanılmasıyla kanserin giderek kronik bir hastalık gibi baş edilebilir hale geleceği görüşünde.

https://t.co/yvpsHIJMIq

[TRT HABER @trthaber]

Kanser tedavisinde umut veren gelişmeler yaşanıyor. Pankreas kanserinde yaşam süresini iki katına çıkarabilen ilaç gündeme geldi.

Uzmanlar, akıllı ilaçların kullanılmasıyla kanserin giderek kronik bir hastalık gibi baş edilebilir hale geleceği görüşünde.

https://t.co/yvpsHIJMIq

[JAMA Oncology @JAMAOnc]

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.

https://t.co/hKB5mKLA6A

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🦴 Euro-EWING99

🌍 N=3,395 | 17 years follow-up

📈 5 years OS
🟢 Localized: 75.2%
🫁 Lung-only M1: 56.0%
🔴 Extrapulmonary M1: 28.1%

🎯 Histologic response and local control remain key prognostic factors.

🔗 https://t.co/GnfrA9qAh8
@OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 NGS in sarcoma

⚠️ Is routine NGS too restricted?

💬 New commentary argues:
🔹 Genomics is often the diagnosis
🔹 Broader NGS access
🔹 Expert interpretation remains essential

🎯 Precision starts with molecular diagnosis.

🔗 https://t.co/NMu48iozW2
@OncoAlert

[Luis Moreno Sánchez @drluismorenos]

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances.

https://t.co/aSWFoomDiI

[MV Chandrakanth @ChandrakanthMv]

EARLY-STAGE NSCLC #ASCO2026

Three key lessons:

✅ RET joins EGFR and ALK as a validated adjuvant target (LIBRETTO-432)

✅ Perioperative lorlatinib may convert unresectable ALK+ disease into a surgical disease (LORIN)

❌ Routine adjuvant nivolumab was not supported in EGFR/ALK-negative resected NSCLC (EA5142)

Test every resected NSCLC.
Target the driver.
Avoid overtreatment.

#LungCancer #NSCLC #ThoracicOncology #PrecisionOncology #ASCO2026 #MVOnco

[Masahiro TORASAWA, MD. PhD. @M_Torasawa]

Seven thoracic oncology studies from #ASCO26 were published simultaneously in leading journals! 🫁✨

Great to see so many major advances in thoracic oncology presented and published at the same time.

#LCSM @OncoAlert

[özkan alan @alan_ozkan]

@barisyarkadas @tv100 Tarih boyunca lanetleneceksiniz

[Dr Rishabh Jain @DrRishabhOnco]

Breast cancer is entering a chemo-free, ADC-driven, ctDNA-guided era.
ESMO Breast 2026 could quietly redefine practice.

Here are 10 trials you should NOT miss 👇

1️⃣ PHERGain-2
🧬 Early HER2+
👉 Chemo-free dual HER2 blockade strategy
🎯 Can we safely omit chemo?

2️⃣ TRAIN-4
🧬 Early HER2+
👉 Anthracycline-free ± escalation
🎯 Is less more?

3️⃣ DESTINY-Breast11
🧬 Neoadjuvant HER2+
👉 Trastuzumab deruxtecan vs standard
🎯 ADC replacing chemo?

4️⃣ HER2CLIMB-02
🧬 HER2+ metastatic
👉 Tucatinib + Trastuzumab emtansine
🎯 Brain mets control

5️⃣ SATEEN
🧬 Post-Trastuzumab deruxtecan setting
👉 Sequencing strategies
🎯 What after T-DXd?

6️⃣ TROPION-Breast04
🧬 HR+/HER2- metastatic
👉 Datopotamab deruxtecan
🎯 Next ADC wave

7️⃣ DESTINY-Breast06 (updates)
🧬 HER2-low / ultra-low
👉 Expanding Trastuzumab deruxtecan
🎯 Redefining HER2 biology

8️⃣ PERSEVERE
🧬 ctDNA-guided early BC
👉 MRD-based escalation/de-escalation
🎯 Precision adjuvant therapy

9️⃣ lidERA (Giredestrant)
🧬 Early ER+
👉 Giredestrant vs standard ET
🎯 SERDs moving early

🔟 CAMBRIA-2
🧬 ER+ high-risk
👉 Camizestrant
🎯 Endocrine backbone changing?

#OncoTwitter #MedTwitter #BreastCancer #ADC
@myESMO @ESMO_Open @stolaney1 @OncoAlert @OncBrothers @Larvol

[MV Chandrakanth @ChandrakanthMv]

"Axillary surgery just to get CDK4/6 inhibitors?"
New ESMO Breast 2026 data says: Not worth it.
Pfob et al. showed:
123 SLNBs to prevent 1 recurrence with ribociclib
106 cALNDs to prevent 1 recurrence with abemaciclib
Even higher numbers for preventing death.
High morbidity, huge costs, marginal benefit.
Practice changer:
Don’t do axillary staging solely for CDK4/6i eligibility in low-risk patients.
#MVOnco #ESMOBreast2026 #BreastCancer

[Dr. Foxpaws Fauxpas @foxpaws_onco]

Let's review a few important uncommon mutations in #nsclc #lung #cancer

MET, RET, KRAS, HER2, BRAF, HER2

Watch out for edema, HTN, pneumonitis with the MET/RET mTKIs!

#lcsm #medtwitter #onctwitter
(Slide 2 courtesy Dr Sumit, Shillong)

[Teoman Yanmaz @mtymtyyanmaz]

Ve beklenen çalışma sonucu geldi. EV+P bu çalışmayla hem tüm neoadjuvant hastalarda (daha önce cis ineligible neoadj’da + çalışması çıkmıştı), hem de metastatik 1. seride en iyi seçenek olduğunu kanıtladı. Cisplatin yıllar sonra mesane kanserinde tahtını devrediyor 👍

[MV Chandrakanth @ChandrakanthMv]

Perioperative IO in MIBC:
EV+pembro shows dramatic EFS vs surgery alone.
Durva+Gem-Cis improves outcomes over chemo.
Different populations. Different controls.
CrCl 50? The real debate begins.
#BladderCancer #GUOnc #MVOnco

[NEJM @NEJM]

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: https://t.co/6M3xhml0ou

Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy https://t.co/3uNr9TUukQ

[IASLC @IASLC]

How is immunotherapy for #NSCLC approached in Türkiye? 🇹🇷
In this episode of #LungCancerConsidered in Turkish, @ececalidaylan sits down with Dr. Irfan Çiçin and @FuldenYumuk1 to discuss immunotherapy strategies for non-small cell lung cancer.
🎧 https://t.co/uvrDEEnY6J

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

🔬 NGS in Sarcoma: Precision ≠ Overtesting
• Sarcoma is not a single disease→routine NGS is NOT precision medicine

Pathology expertise matters more than large gene panels.

Most NGS results don't change management outside selected subtypes.
@OncoAlert
https://t.co/F7XZctyUrZ

[Diego A. Díaz-García @diegoadiazg]

🧠 Glioblastoma in adults: consensus update.

🔹SNO and EANO review current management and future directions in adult glioblastoma, now restricted to IDH wild type tumors per WHO 2021. Standard therapy remains surgery plus RT and temozolomide, with limited OS benefit.
🔹Novel strategies include immunotherapy, viral therapies, targeted agents, theranostics, and ADCs.
🔹Key challenges persist in heterogeneity, immune resistance, and BBB penetration.

📖 @JNeurooncol
DOI 👉🏻 10.1093/neuonc/noaf177/8237727

#CánCare #glioblastoma #neurooncology #oncology #braincancer #molecularoncology

[Yakup Ergün @dr_yakupergun]

Management of Cancer During Pregnancy: ASCO Guideline

It is a remarkably comprehensive guide that addresses every question thoroughly👇
https://t.co/NXtQjTcsIb

[Dr Rishabh Jain @DrRishabhOnco]

🧠✨ STELLAR Trial (JCO 2025): A Big Win for Recurrent IDH-mut Grade 3 Astrocytoma

🚨 Huge neuro-oncology update!
Adding Eflornithine + Lomustine shows major survival gains but only in the right molecular group.
Let’s break it down 👇🧬

🎯 Trial Essentials
📌 Phase III, randomized, open-label
👥 343 patients, recurrent grade 3 astrocytoma
💉 Prior RT + TMZ

🔀 Arms:
•💊 Eflornithine + Lomustine
•💊 Lomustine alone

🎯 Primary endpoint: OS

🧠 Reclassified per WHO 2021 into:
•IDH-mut Grade 3
•IDH-mut Grade 4 (CDKN2A/B del)
•IDH-wt GBM

🔥 Key Results (IDH-mut Grade 3 - the REAL target group)
✨ Defined before unblinding as the biologically appropriate subset

🕒 OS: 34.9 vs 23.5 months
➝ +11.4 months ⭐
➝ HR 0.64

🧭 PFS: 15.8 vs 7.2 months
➝ >2× improvement 🚀
➝ HR 0.57

📈 Higher radiographic responses
⚠️ No benefit in IDH-mut Grade 4 or IDH-wt GBM (expected for cytostatic therapy)

🧬 Mechanism (Why it Works)
Eflornithine = ODC inhibitor ❌🧪 polyamine synthesis
👉 Cytostatic, not cytotoxic
👉 Works best in slower-growing IDH-mut Grade 3 tumors
👉 Perfect biological match with the results

⚠️ Safety (Manageable)
•🩸 Myelosuppression: 42% vs 29%
•👂 Hearing impairment: 24% vs 0% (mostly reversible)
•🤢 Diarrhea, nausea, fatigue (expected)
•❗No grade 5 events

📌 Takeaway
For recurrent IDH-mut Grade 3 astrocytoma
➡️ Eflornithine + Lomustine = meaningful survival advantage 🧠💪
A potential new option in a setting with very limited therapies.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #NeuroOncology #Glioma
@OncoAlert @myesmo @esmo_open @ASCO @JournalofCO